NVCR NovoCure Ltd
Price Chart
Executive Summary
NovoCure held its 2026 annual general meeting on June 3, 2026, re-electing all 11 director nominees and approving the Amended and Restated 2024 Omnibus Incentive Plan by a razor-thin margin (50.3% for vs. 49.7% against). The omnibus plan approval was highly contested, with nearly as many votes against as for, signaling significant shareholder dissent on equity compensation. The filing is routine in nature but the close vote on the incentive plan is a notable governance signal.
Actionable Insight
The near-50/50 split on the omnibus incentive plan is a governance red flag — watch for potential shareholder lawsuits or proxy advisor downgrades. The board re-election was clean, so no immediate activist catalyst. Monitor next 10-Q for any accelerated equity grant activity under the newly approved plan.
Key Facts
- All 11 director nominees were elected with strong support (lowest 'for' vote was 79,455,754 for Kinyip Gabriel Leung).
- The Amended and Restated 2024 Omnibus Incentive Plan was approved with 41,680,622 votes for and 41,161,139 against — a margin of only 519,483 shares (50.3% for).
- Shareholder turnout was 81.01% (93,826,730 shares voted).
- The omnibus plan authorizes up to 18,000,000 ordinary shares for future equity awards, less shares granted under the prior plan after April 2, 2024.
- Executive compensation (say-on-pay) passed with 75,392,168 for vs. 7,422,876 against (91% approval).
- Kost Forer Gabbay & Kasierer (EY Global) was ratified as auditor with 91,436,910 votes for.
Financial Impact
No direct financial impact. The omnibus plan authorizes up to 18M shares for future equity grants, but no specific grants were disclosed in this filing.
Risk Factors
- High shareholder dissent on equity plan could lead to increased scrutiny of future compensation proposals or a withhold-vote campaign against compensation committee members.
- The omnibus plan's 18M share reserve represents approximately 15.5% of current shares outstanding — potential dilution risk if fully utilized.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001645113-26-000050 |
| Document: nvcr-20260603.htm | 0001645113-26-000050 |
| Document: 0001645113-26-000050-index-headers.html | 0001645113-26-000050 |
| Document: 0001645113-26-000050-index.html | 0001645113-26-000050 |
| Document: 0001645113-26-000050.txt | 0001645113-26-000050 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
7d ago
|
8-K
| $17.17 awaiting T+1 | awaiting T+1 | — | $17.78 (+3.55%) |
|
Jun 3, 2026
9d ago
|
Insider Cluster
| $17.99 $17.16 | ▼ −4.61% | ▼ −2.04% | $17.78 (−1.17%) |
|
Jun 3, 2026
9d ago
|
Insider Cluster
| $17.99 $17.16 | ▼ −4.61% | ▼ −2.02% | $17.78 (−1.17%) |
|
Apr 20, 2026
7w ago
|
DEFA14A
| $12.23 $13.02 | ▲ +6.46% | ▲ +5.44% | $17.78 (+45.38%) |
|
Feb 27, 2026
15w ago
|
Insider Cluster
| $13.67 $13.52 | ▼ −1.10% | ▼ −1.15% | $17.78 (+30.07%) |
|
Feb 27, 2026
15w ago
|
Insider Cluster
| $13.67 $13.52 | ▲ +1.10% | ▲ +1.15% | $17.78 (−30.07%) |
|
Feb 27, 2026
15w ago
|
Insider Cluster
| $13.67 $13.52 | ▼ −1.10% | ▼ −1.15% | $17.78 (+30.07%) |
|
Feb 26, 2026
15w ago
|
8-K
| $13.75 $13.67 | ▼ −0.58% | ▼ −0.13% | $17.78 (+29.31%) |
|
Feb 24, 2026
15w ago
|
8-K
| $14.99 $13.75 | ▼ −8.27% | ▼ −7.73% | $17.78 (+18.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access